Home Search

prostate cancer - search results

If you're not happy with the results, please do another search

Moffitt Researchers Uncover Prostate Cancer Resistance Mechanism

Moffitt Cancer Center researchers showed that prostate cancer cells become resistant through molecular modification of the androgen receptor protein and identified a potential treatment approach that could overcome this resistance in mice.

Newly Found Unknown Subtype of Hormone-Resistant Prostate Cancer Reveals Potential Targets

The researchers call the newly characterized third subtype stem cell-like (SCL), because some of the genes that are turned on in the cells are reminiscent of those in stem cells.
GenomeDx Biosciences has agreed to pay the U.S. federal government $1.99 million to settle allegations that it submitted false claims to Medicare for the Decipher post-operative genetic test for prostate cancer patients. [National Cancer Institute

Researchers Detail Clues to Prostate Cancer Therapy Resistance, ID New Treatment Strategy

This study revealed that antiandrogen therapy induces viral mimicry responses that are crucial for antitumor activity.
PSA positive

Genetic PSA Score May Improve Prostate Cancer Screening Accuracy

Incorporating genetic factors that influence prostate-specific antigen (PSA) level into prostate cancer screening may help reduce unnecessary invasive testing and improve the detection of aggressive disease.
A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA. [Darryl Leja

Potential Approach for Prostate Cancer Treatment Uncovered

Researchers at CAS Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences demonstrated in mouse models the oncometabolite role of progesterone in advanced prostate cancer and strategies to eliminate its oncogenic effect.
Conceptual image for viral ethiology of prostate cancer

Prostate Cancer and Treatment Differs in Black Men

Black men with prostate cancer may respond well to androgen deprivation therapy (ADT)-based regimens, but they are less likely to receive such therapy than non-Blacks, according to a new multi-institutional retrospective analysis.

Hormone-Sensitive Prostate Cancer Patients Survival Improved with Combination Therapy

A Phase III clinical trial led by scientists at Massachusetts General Hospital showed that adding darolutamide to androgen-deprivation therapy and chemotherapy extended the survival of men with metastatic, hormone-sensitive prostate cancer.
Loyal Golden Retriever Dog Sitting on a Green Backyard Lawn, Looks at Camera. Top Quality Dog Breed Pedigree Specimen Shows it's Smartness, Cuteness, and Noble Beauty. Colorful Portrait Shot

Prostate Cancer Similarities Between Man and Dog Helps ID New Drug Target

In a first-of-its-kind study on dogs with naturally occurring prostate cancer, scientists have discovered that blocking CCR4 expressing regulatory T cells that infiltrate tumors and prevent other immune cells from annihilating tumor cells, may be a promising therapeutic strategy for advanced prostate cancer in dogs and a subset of human patients.
Prostate cancer, illustration

Optimal High-Risk Prostate Cancer ADT Duration May Be Radiotherapy-Dependent

The analysis, which combined individual patient data from three different cohorts, showed that men receiving high-dose external beam radiotherapy (EBRT) alone may benefit from at least 18 months of ADT whereas those who receive EBRT plus a brachytherapy boost may be optimally managed with 18 months of ADT or less.
Image on screen of cancer screen. Artificial intelligence (AI) can be used in software that helps a pathologist interpret features of cancer in digitized images of samples.

Open Data Collaboration Shows AI Can Accurately Diagnose Prostate Cancer

A large study led by the Karolinska Institute in Sweden shows that artificial intelligence can be used to accurately diagnose and grade prostate cancer in a way that is generalizable across different populations.